Clinical Research Directory
Browse clinical research sites, groups, and studies.
TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis
Sponsor: Tarian Pharma
Summary
A Phase II, multicentric, randomized, double-blind, placebo-controlled, parallel- group trial to confirm the good safaty profile and to explore the preventive effect of topically applied TAR-0520 gel on folliculitis developed in metastatic colorectal cancer (mCRC) patients treated with monoclonal anti-EGFR antibodies.
Official title: A Phase II Multicentric, Randomized, Double-blind, Placebo-controlled Study of TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis.
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2025-01-20
Completion Date
2026-09-30
Last Updated
2025-02-10
Healthy Volunteers
No
Conditions
Interventions
Brimonidine tartrate Gel
Once daily applications for 7 days
Placebo gel (no Brimonidine tartrate)
Once daily applications for 7 days
Locations (3)
Hopital Privé Jean Mermoz
Lyon, France
Institut Paoli Calmette
Marseille, France
Centre Antoine Lacassagne
Nice, France